For the First Time in the World: Stem Cell Transplant Leads to Diabetes Remission

In 2021, a team of Chinese scientists and clinicians successfully treated a diabetes patient using an innovative stem cell transplant.
The treatment, based on endodermal stem cells derived from the patient's own peripheral blood mononuclear cells (PBMCs), offers new hope for diabetes patients worldwide.

The Patient:

The patient, a 59-year-old man, had type 2 diabetes for 25 years.
Although he received a kidney transplant in 2017, he lost most of his pancreatic islet function, leading to severe dependence on multiple daily insulin injections.
Importantly, due to the kidney transplant, the patient was already on immunosuppressive therapy, which facilitates the acceptance of the transplanted cells and complicates comparison to patients who are not immunosuppressed.

The Treatment:

The treatment involved transplanting the patient's own peripheral blood mononuclear cells.
These cells were reprogrammed using advanced technologies and converted into endodermal stem cells (referred to as "seed cells"), with properties similar to pancreatic islet cells intended for insulin production.
Subsequently, the cells were transplanted into the patient's body, where they developed into functional pancreatic islet tissue.

Results:

The results were promising.
Within just 11 weeks after the transplant, the patient no longer needed external insulin.
Within a year, his need for oral medications to control blood sugar levels was completely eliminated.
However, this is a single case that was also under immunosuppression, so it is more accurate to describe this as remission and insulin independence in a single case, rather than a proven cure for the disease.

Significance of the Treatment:

The success of this treatment represents a significant advancement in the field of diabetes therapy.
It offers a new possibility to help patients who do not respond to existing treatments and to reduce their dependence on chronic medications.
Nevertheless, further studies with a larger number of patients are needed to determine if this is a sustainable and safe long-term treatment.

What Are "Seed Cells":

Contrary to common understanding, the term "seed cells" does not refer to sperm cells in the biological sense.
These are peripheral blood mononuclear cells (PBMCs) that have undergone a process of reprogramming and conversion into endodermal stem cells with properties similar to pancreatic islet cells.

Advantages of Cell Therapy:

• Personalized Treatment: Peripheral blood mononuclear cells are taken from the patient themselves, reducing the risk of rejection.
• Insulin Production: The transplanted cells are capable of naturally producing insulin, which can regulate blood sugar levels.
• Avoidance of Side Effects: Personalized cell therapy may be less invasive than transplants from a foreign donor, with a lower risk of immune rejection.

Challenges:

• Further Research: Additional research is needed to understand the long-term efficacy and safety of this treatment.
• Costs: Cell therapy is still relatively expensive, and methods to reduce its cost need to be developed.
• Accessibility: The treatment needs to be made more accessible to patients worldwide.

In Summary:

Endodermal stem cell transplantation offers new hope for diabetes patients.
The treatment has shown promising results in a human for the first time, and it has the potential to improve the quality of life for many patients.
However, this is still a single case under immunosuppression, and further research and development of new technologies are needed to make the treatment safe, accessible, and affordable for all.

References:
Treating a type 2 diabetic patient with impaired pancreatic islet function by personalized endoderm stem cell-derived islet tissue, Cell Discovery (2024)
https://stcsm.sh.gov.cn/news/20240513/640613715b914a2eb735a32a35215afb.html